Phoenix Life Announces Annual Financial Report Filings for 2017 and
2018
DENVER, CO –
April 26, 2019 -- InvestorsHub NewsWire
-- –
Phoenix Life Sciences International Limited (OTC: PLSI) ("Phoenix Life", the
"Company"), an international adaptive healthcare solutions company,
today announced that it has completed filing its Form 10-Quarterly Reports
and
Form 10-K Annual
Reports, including audited financial reports, with the Securities
and Exchange Commission ("SEC")
for the 2017 and
2018 fiscal years as part of the Company's 2018
merger and
consolidation.
Phoenix Life was
created through a consolidation of multiple domestic and
international businesses. The filing of these 2017 and 2018
reports, and subsequent quarterly
reports will bring the Company
current
with
its reporting
requirements with the SEC. Phoenix Life intends to
remain a fully reporting
public company to
provide full
transparency with the SEC and investing public.
Following OTC
Markets update of reporting status to Current, Phoenix Life intends to
begin the process
of uplisting onto the OTCQB
market, in
parallel with launching a capital offering to fund the next stages
of development and execution for the Company.
"The Phoenix Life
team has been working diligently to bring the reports of the Company current
including all reports pre and post-merger. Complete transparency in all
aspects of our business remains a high priority," said Martin
Tindall, CEO and Founder of Phoenix Life. "As Phoenix Life moves forward
with the legal global distribution of its medical cannabis derived
pharmaceutical products and programs for managing healthcare, our
underlying corporate compliance is a key priority for the
Company."
In March 2019,
Phoenix Life
announced the filing its 2015 and 2016
Form 10-K Annual Reports.
The Company is
currently performing widespread diabetes screenings across the
Republic of Vanuatu in advance of launching
clinical trials on
the efficacy of its diabetes treatment in conjunctuion
with leading
Australian Universities and Ethics Committees.
To learn more about
Phoenix Life Sciences International, please visit https://phoenixlife.co/.
###
About Phoenix
Life Sciences International Limited
Phoenix Life
Sciences International Limited is an adaptive healthcare solutions
company. Our business is to advance research and integrate programs
and manufacturing of products that target and treat diabetes, pain,
cancer, and address psychological, gastrointestinal, autoimmune,
neurological and sleep disorders. We strive to create partnerships
and integrate these programs for human health into communities
worldwide as part of our Global Health Initiative.
FORWARD-LOOKING
STATEMENTS
Information
contained in this press release regarding Phoenix Life Sciences
International, Limited and its subsidiaries, (the "Companies") may
constitute forward-looking statements or statements which may be
deemed or construed to be forward-looking statements. The words
"plan", "forecast", "anticipates", "estimate", "project", "intend",
"expect", "should", "believe," and similar expressions are intended
to identify forward-looking statements. These forward-looking
statements involve, and are subject to, known and unknown risks,
uncertainties and other factors which could cause the Company's
actual results, performance (financial or operating) or
achievements to differ from the future results, performance
(financial or operating) or achievements expressed or implied by
such forward-looking statements. The risks, uncertainties and other
factors are more fully discussed in the Company's filings with the
U.S. Securities and Exchange Commission. All forward-looking
statements attributable to the Companies herein are expressly
qualified in their entirety by the above-mentioned cautionary
statement. The Companies disclaim any obligation to update
forward-looking statements contained in this press release, except
as may be required by law.
FOOD AND DRUG
ADMINISTRATION (FDA) DISCLOSURE
These statements
have not been evaluated by the FDA and therefore the products sold
by Phoenix Life Sciences International are not available in the
U.S.
LEGAL
DISCLOSURE
Phoenix Life
Sciences International does not sell or distribute any products in
the United States that are in violation of the United States
Controlled Substances Act (US.CSA). This company does not grow,
sell, and distribute cannabis-based products in the United States
and is solely involved with the legal distribution of medical
cannabis-based products within certain international markets
outside of the United States.
Investor
Contact:
Phone:
1.888.717.5655 or international +1.720.699.7222
E-mail:
investor.relations@phoenixlife.co
Media
Contact:
Kathryn
Reinhardt
CMW
Media
Kathryn@cmwmedia.com
619-972-3089